Dark

Check out our API

ATNF
180 Life Sciences Corp. Common Stock
stock NASDAQ

Inactive

Aug 15, 2025

7.04USD-7.490%(-0.57)11,633,983

Pre-market

0.00USD-100.000%(-7.61)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

08:09AM EST 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter To Shareholders Benzinga

08:00AM EST 180 Life Sciences Corp. (NASDAQ:ATNF, 180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to shareholders from its Chief Executive Officer, Dr. James Woody. GlobeNewswire Inc

Jan 27, 2022

05:01AM EST 41 Biggest Movers From Yesterday Benzinga

Dec 28, 2021

11:00AM EST 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. GlobeNewswire Inc

Dec 15, 2021

08:16AM EST 180 Life Sciences Enters Into License Agreement With University Of Oxford For Regenerative Molecule HMGB1 For Liver Diseases; Terms Not Disclosed Benzinga

08:15AM EST 180 Life Sciences Corp. Enters into a License Agreement with GlobeNewswire Inc

Dec 6, 2021

08:17AM EST 180 Life Sciences Provides Follow-Up Information On Oxford University, Co's Dupuytren's Phase 2b Clinical Trial Results Benzinga

08:15AM EST 180 Life Sciences Provides Follow-Up Information on Oxford GlobeNewswire Inc

Dec 1, 2021

02:45PM EST 180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal GlobeNewswire Inc

08:41AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case Benzinga

08:36AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case Benzinga

Nov 28, 2021

09:43AM EST The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week Benzinga

Nov 22, 2021

08:33AM EST 180 Life Sciences Reports Extension Of Its Patent Portfolio With Recent Grant Of New Patents To Yissum Research Development Co. Of Hebrew University In US, Canada Benzinga

08:30AM EST 180 Life Sciences Corp. Expands Patent Portfolio GlobeNewswire Inc

Nov 18, 2021

08:15AM EST 180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to GlobeNewswire Inc

Nov 3, 2021

12:12PM EDT 180 Life Sciences Names Quan Vu COO Benzinga

12:07PM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. GlobeNewswire Inc

Oct 26, 2021

08:39AM EDT 180 Life Sciences Corp. Publishes Pre-Clinical Study Report On Effects Of CBG Derivatives On Pain, Inflammation And Obesity In The Journal Molecules Benzinga

08:30AM EDT 180 Life Sciences Corp. Publishes Pre-Clinical GlobeNewswire Inc

Sep 30, 2021

08:42AM EDT 180 Life Sciences Corp. Receives Notice Of Allowance For 'Method for Reducing Post-Operative Cognitive Dysfunction (POCD)' Benzinga

08:30AM EDT 180 Life Sciences Corp. Continues To Expand Intellectual Property GlobeNewswire Inc

Sep 20, 2021

04:39PM EDT 180 Life Sciences 8-K Shows Co. Entered Settlement, Mutual Release Deal With Mintz, Levin, Cohn, Ferris, Glovsky, Popeo; Co. To Pay Mintz $800K In Cash Benzinga

08:09AM EDT Celltrion Healthcare And 180 Life Sciences Enter Into Memorandum Of Understanding For A Supply Agreement For The Ongoing Supply Of Drug For Anti-TNF Product Trials For Novel Indications Benzinga

08:00AM EDT Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum GlobeNewswire Inc

Sep 15, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021 Benzinga

08:38AM EDT Maxim Group Initiates Coverage On 180 Life Sciences with Buy Rating, Announces Price Target of $11 Benzinga

Sep 1, 2021

11:44AM EDT 180 Life Sciences Option Alert: Nov 19 $12.5 Calls Sweep (7) near the Ask: 1357 @ $0.25 vs 3193 OI; Ref=$6.5 Benzinga

Aug 31, 2021

12:44PM EDT 180 Life Sciences Option Alert: Feb 18 $5 Calls Sweep (17) near the Ask: 200 @ $1.801 vs 196 OI; Ref=$5.83 Benzinga

Aug 30, 2021

08:30AM EDT 180 Life Sciences Corp. (NASDAQ:ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. GlobeNewswire Inc

Aug 25, 2021

12:31PM EDT 180 Life Sciences Option Alert: Jan 21 $5 Calls Sweep (12) near the Ask: 200 @ $1.25 vs 758 OI; Ref=$5.32 Benzinga

Aug 24, 2021

08:30AM EDT 180 Life Sciences Corp. Announces Closing of $15.0 Million Private GlobeNewswire Inc

Aug 19, 2021

09:13AM EDT 180 Life Sciences Corp. Announces $15M Private Placement Benzinga

09:00AM EDT 180 Life Sciences Corp. Announces $15.0 Million Private Placement GlobeNewswire Inc

Aug 2, 2021

08:01AM EDT EXCLUSIVE: 180 Life Sciences Clinical Advisory Board Chairman Invited At The British Society For Surgery Benzinga

08:00AM EDT EXCLUSIVE: 180 Life Sciences Chairman Of Clinical Advisory Board, Jagdeep Nanchahal, To Present A Keynote Talk At British Society For Surgery Of The Hand On Sept. 9 Benzinga

08:00AM EDT Chairman of the 180 Life Sciences Clinical Advisory Board, GlobeNewswire Inc

Jul 31, 2021

08:56PM EDT The Week In Cannabis: Tilray's Huge Week, Colin Hanks, Allen Iverson, Seth Rogen And More Benzinga

Jul 29, 2021

08:00AM EDT 180 Life Sciences to Participate in Fireside Chat at BTIG Virtual GlobeNewswire Inc

Jul 28, 2021

08:37AM EDT EXCLUSIVE: 180 Life Sciences Identifies New Patentable CBD Analog For Drug Development For Treating Inflammation, Pain Benzinga

08:15AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain. GlobeNewswire Inc

08:02AM EDT EXCLUSIVE: 180 Life Sciences Identifies New Patentable CBD Analog For Drug Development For Treating Inflammation, Pain Benzinga

08:00AM EDT EXCLUSIVE: 180 Life Sciences Announces Co Has Selected Lead Synthetic CBD Analog That Is Expected To Move Forward In Clinical Development For Both Inflammation And Pain Benzinga

Jul 20, 2021

04:36PM EDT 180 Life Sciences S-1 Shows Registration For ~5.44M Share Common Stock Offering Via Selling Shareholders Benzinga

08:13AM EDT 180 Life Sciences Reports Regained Nasdaq Compliance Benzinga

08:00AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has regained Nasdaq Compliance under listing rule 5250(c)(1). GlobeNewswire Inc

Jul 12, 2021

09:51AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2). GlobeNewswire Inc

Jul 7, 2021

08:00AM EDT 180 Life Sciences Expands Scientific Fibrosis Platform with GlobeNewswire Inc

Jun 28, 2021

08:19AM EDT 180 Life Sciences Joins Russell Microcap Index Benzinga

08:15AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has joined the Russell MicrocapIndex, effective after the U.S. market opens today, June 28. GlobeNewswire Inc

08:00AM EDT 180 Life Sciences Files Plan with Nasdaq Related to Delayed GlobeNewswire Inc

Jun 10, 2021

09:12AM EDT 180 Life Sciences Corp. Announces the Appointment of Pamela GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021. GlobeNewswire Inc

May 28, 2021

08:06AM EDT 180 Life Sciences Appoints Russell Ray And Teresa DeLuca To Its Board RTTNews

08:00AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors (Board) effective June 15, 2021. GlobeNewswire Inc

May 21, 2021

04:45PM EDT 180 Life Sciences Corp. Receives Expected Notification From Nasdaq GlobeNewswire Inc

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

08:02AM EDT 180 Life Sciences Corp. Announces Collection Of All Patient Data For Phase 2b Dupuytren's Disease Trial Benzinga

08:00AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that all patient data for the Phase 2b Dupuytrens disease clinical trial has been collected and submitted for analysis and review. GlobeNewswire Inc

Apr 19, 2021

05:00PM EDT 180 Life Sciences Corp. Receives Expected Notification From Nasdaq GlobeNewswire Inc

Apr 14, 2021

08:15AM EDT 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Lynn Williams, Ph.D., has been awarded the International Dupuytren Award 2021 for Basic Research. GlobeNewswire Inc

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 12, 2021

03:26PM EDT What's Happening With ATNF Stock And CELC Stock? Benzinga

Mar 26, 2021

10:38AM EDT Mid-Morning Market Update: Markets Open Higher; Madison Square Garden To Acquire MSG Networks Benzinga

08:34AM EDT 180 Life Sciences Reports Availability Of Broadcast 'Controlling Inflammation to Stop Disease'; Press Release Notes Founding Team Members Of Co. 'recognized pioneers of research and development in anti-inflammatory therapeutics' Benzinga

08:30AM EDT NetworkNewsAudio 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, Controlling Inflammation to Stop Disease. GlobeNewswire Inc

Mar 25, 2021

08:30AM EDT via InvestorWire 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (IBN), a multifaceted financial news and publishing company for private and public entities. GlobeNewswire Inc

Mar 24, 2021

08:35AM EDT 180 Life Sciences CEO Issues Letter To Shareholders (Full Letter) Benzinga

08:30AM EDT 180 Life Sciences Corp. (NASDAQ:ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3 clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. GlobeNewswire Inc

Mar 10, 2021

11:58AM EST 180 Life Sciences Option Alert: Aug 20 $7.5 Calls Sweep (3) near the Ask: 250 @ $1.0 vs 1258 OI; Earnings 5/3 Before Open [est] Ref=$5.49 Benzinga

Mar 8, 2021

01:30PM EST 180 Life Sciences Corp. to Present at Inaugural Emerging Growth GlobeNewswire Inc

Feb 24, 2021

04:00PM EST 180 Life Sciences Corp. Announces Closing of $11.7 Million Private GlobeNewswire Inc

Feb 19, 2021

09:04AM EST 180 Life Sciences Corp. Announces 2,564,000 Unit Private Placement At $4.55/Unit Benzinga

09:00AM EST 180 Life Sciences Corp. Announces $11.7 Million Private Placement GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Jan 6, 2021

04:45PM EST 180 Life Sciences Corp Says Working To Rectify Nasdaq Listing Deficiencies By Locating And Appointing Two Independent Directors Benzinga

Jan 5, 2021

02:50PM EST 180 Life Sciences Corp. (NASDAQ:ATNF)(180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference. GlobeNewswire Inc

Dec 3, 2020

11:08AM EST 180 Life Sciences Corp. (NASDAQ:ATNF)("180 Life Sciences" or "the Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it will participate in the LD Micro Virtual Main Event 2020 Conference. GlobeNewswire Inc

Nov 24, 2020

10:00AM EST 180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November GlobeNewswire Inc

Nov 23, 2020

08:30AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. GlobeNewswire Inc

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

08:00AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. GlobeNewswire Inc

Nov 10, 2020

11:46AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. GlobeNewswire Inc

Nov 9, 2020

02:30PM EST Mid-Afternoon Market Update: Dow Surges Over 1300 Points; Arcturus Therapeutics Shares Slide Benzinga

12:40PM EST Mid-Day Market Update: Crude Oil Jumps Over 9%; HighPoint Resources Shares Plummet Benzinga

10:15AM EST Mid-Morning Market Update: Markets Open Higher; Pfizer-BioNTech's COVID-19 Vaccine Candidate Is 90% Effective Benzinga

Share